Bioventus
4721 Emperor Boulevard
Suite 100
Durham
North Carolina
27703
United States
Website: https://www.bioventus.com/
120 articles about Bioventus
-
Bioventus to Present at the Canaccord Genuity Musculoskeletal Conference
3/16/2022
Bioventus Inc. (Nasdaq: BVS), a global leader in innovations for active healing, today announced that Ken Reali, chief executive officer, will participate in a fireside chat at the Canaccord Genuity Musculoskeletal Conference on Tuesday, March 22, 2022, at 11:00 a.m. ET.
-
Bioventus Reports Fourth Quarter and Full Year 2021 Financial Results; Introduces Full Year 2022 Financial Guidance
3/10/2022
Bioventus Inc., a global leader in innovations for active healing, reported financial results for the fourth quarter and full-year ended December 31, 2021.
-
Bioventus Receives 510(k) Clearance for StimRouter Pain Management DeviceIndustry Leading Peripheral Nerve Stimulator Upgraded to Improve Patient User Experience with Control of their Unique Chronic Pain Condition, Longer Battery Life
3/1/2022
Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, announced that the US Food and Drug Administration (FDA) has awarded 510(k) clearance to the next generation StimRouter® Neuromodulation System for the treatment of chronic pain of peripheral nerve origin, excluding craniofacial pain.
-
Bioventus Appoints Mark Singleton as Chief Financial Officer
2/28/2022
Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, today announced that it has appointed Mark Singleton as the Company’s Senior Vice President, Chief Financial Officer and Principal Accounting Officer, effective March 21, 2022.
-
Bioventus to Report Fourth Quarter and Fiscal Year 2021 Financial Results on March 10, 2022
2/22/2022
Bioventus Inc. today announced that it will report financial results for the fourth quarter and fiscal year 2021 before the market opens on Thursday, March 10, 2022.
-
Bioventus Announces Preliminary Fourth Quarter and Full-Year 2021 Revenue
1/11/2022
Bioventus Inc. announced today preliminary revenue results for the fourth quarter and full-year 2021.
-
Bioventus to Present at the 40th Annual J.P. Morgan Healthcare Conference
12/28/2021
Bioventus Inc. (Nasdaq: BVS), a global leader in innovations for active healing, today announced that Ken Reali, chief executive officer, will present at the 40th Annual J.P. Morgan Healthcare Conference via webcast on Wednesday, January 12, 2022, at 5:15 p.m. ET.
-
Bioventus Appoints Michelle McMurry-Heath to Board of Directors
12/21/2021
Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, has announced the appointment of Michelle McMurry-Heath, MD, PhD, to the Company’s Board of Directors, effective January 1, 2022.
-
Bioventus Receives US FDA Clearance for BoneScalpel® Access™
12/20/2021
Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, announced the US Food and Drug Administration (FDA) has granted 510(k) clearance for the Company’s neXus® BoneScalpel® Access™ handpiece.
-
Bioventus Reports Third Quarter Results; Updates Full-Year 2021 Financial Guidance
11/9/2021
Bioventus Inc. (Nasdaq: BVS) ("Bioventus" or "the Company"), a global leader in innovations for active healing, today reported financial results for three and nine months ended October 2, 2021.
-
Sharon Klugewicz Joins Bioventus as Senior Vice President, Quality and Regulatory Affairs
11/1/2021
Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, has appointed Sharon Klugewicz as Senior Vice President, Quality and Regulatory Affairs.
-
Bioventus Completes the Acquisition of Misonix
10/29/2021
Bioventus Inc. has completed the acquisition of Misonix, Inc. (“Misonix”), a provider of minimally invasive therapeutic ultrasonic technologies and regenerative medicine that are designed to enhance clinical outcomes, for cash and common stock.
-
Bioventus and Misonix Stockholders Approve the Acquisition of Misonix by Bioventus
10/26/2021
Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), and Misonix, Inc. (Nasdaq: MSON) (“Misonix”), today announced that the stockholders of Bioventus approved the issuance of shares of Bioventus class A common stock to the stockholders of Misonix in connection with the previously announced Agreement and Plan of Merger, dated July 29, 2021,
-
Bioventus Proceeds with Option Structure Agreement with CartiHeal
8/30/2021
Bioventus Inc. has elected to make a $50 million escrow payment pursuant to its Option and Equity Purchase Agreement with CartiHeal Ltd., signaling its intent to move forward with an acquisition of CartiHeal.
-
Bioventus Reports Second Quarter Results; Updates Full Year 2021 Financial Guidance
8/10/2021
Bioventus Inc. (Nasdaq: BVS) ("Bioventus" or "the Company"), a global leader in innovations for active healing, today reported financial results for three and six months ended July 3, 2021.
-
Bioventus Launches OSTEOAMP® SELECT Flowable Nationwide
7/13/2021
Bioventus Inc., a global leader in innovations for active healing, is launching OSTEOAMP SELECT Flowable, a flowable allograft bone graft substitute solution developed for a variety of patient procedures including lumbar spine fusion, cervical spine fusion and foot & ankle fusion.
-
Bioventus Invests in VaporoxUltrasonic Technology to Heal Diabetic Foot Ulcers
6/24/2021
Bioventus Inc. has completed a minority investment in Vaporox , Inc., a developer of a highly innovative diabetic foot ulcer (“DFU”) wound healing therapy.
-
Bioventus to Release Second Quarter of Fiscal Year 2021 Financial Results on August 10, 2021
6/16/2021
Bioventus Inc.today announced that second quarter of fiscal year 2021 financial results will be released after the market closes on Tuesday, August 10, 2021.
-
Bioventus Study Shows Novel Placental Tissue Biologic Candidate Inhibited Inflammatory and Catabolic Responses In VitroDemonstrated Significant Reduction of Pain and Cartilage Degeneration in Rat Osteoarthritis Model
5/25/2021
Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, announced human placental tissue, prepared as a particulate composition, termed PTP-001, was shown to contain an array of beneficial growth factors, cytokines and anti-inflammatory molecules, which significantly reduced pain and cartilage degeneration in a rat osteoarthritis (OA) model.
-
Bioventus Inc. Reports First Quarter Results; Updates Full Year 2021 Financial Guidance
5/12/2021
Bioventus Inc. (Nasdaq: BVS) ("Bioventus" or "the Company"), a global leader in innovations for active healing, today reported financial results for three months ended April 3, 2021.